Article
Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy - 1 Dec 2014
Kikuchi Kan, Akiba Takashi, Nitta Kosaku, Masakane Ikuto, Ando Ryoichi, Izumi Namiki, Atsukawa Masanori, Yamazaki Chikao, Kato Fumi, Hotta Naoki, Tominaga Yoshihiro, Orito Etsuro, Hora Kazuhiko, Nagasawa Masaki, Kasahara Hiroshi, Kawaguchi Masanori, Kimura Hiroyuki, Ikebe Norisato, Kawanishi Hideki, Moriishi Misaki, Shigemoto Kenichiro, Harada Takashi, Hirakata Hideki, Watanabe Hiroshi, Nosaki Tsuyoshi, Tsubouchi Hirohito, Imawari Michio, Akizawa Tadao
Abstract excerpt
Many studies have reported poor vital prognosis in hepatitis C virus (HCV)-infected dialysis patients. The rate of HCV-infected dialysis patients in Japan is as high as 9.8%, and antiviral therapy is believed to be important for improving vital prognosis. We conducted a multicenter study to examine the administration method for pegylated interferon α-2a (PEG-IFNα-2a) monotherapy in HCV-infected dialysis. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.